Brief: Solid Biosciences Gets FDA IND, Health Canada CTA Nod for First-In-Class Cardiac Gene Therapy CPVT
08/07/2025 22:28
July 8 (Reuters) - Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES ANNOUNCES FDA IND AND HEALTH CANADA CTA APPROVAL FOR FIRST-IN-CLASS CARDIAC GENE THERAPY TO TREAT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) SOLID BIOSCIENCES INC - EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN Q4 OF 2025 SOLID BIOSCIENCES INC - PHASE 1B CLINICAL TRIAL FOR SGT-501 EXPECTED IN Q4 2025 SOLID BIOSCIENCES- EXPANDS SOLID'S CLINICAL PIPELINE TO INCLUDE FIRST CARDIAC INDICATION WITH URGENT UNMET MEDICAL NEED Source text: ID:nGNX77LwZJ Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsMarketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs
Solid Biosciences Q4 net loss widens on higher R&D costs
NASDAQ RESUMED AT 01:58 PM
Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial